Literature DB >> 22134238

Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop.

Fabio Valenti1, Francesca Fausti, Francesca Biagioni, Tal Shay, Giulia Fontemaggi, Eytan Domany, Michael B Yaffe, Sabrina Strano, Giovanni Blandino, Silvia Di Agostino.   

Abstract

Aberrant activation of kinases has emerged to be a key event along with tumor progression, maintenance of tumor phenotype and response to anticancer treatments. This study documents the existence of an oncogenic auto-regulatory feedback loop that includes the Polo-like kinase-2 (Snk/Plk2) and mutant p53 proteins. Plk2 protein binds to and phosphorylates mutant p53, thereby potentiating its oncogenic activities. Phosphorylated mutant p53 binds more efficiently to p300 consequently strengthening its own transcriptional activity. Plk2 gene is regulated at a transcriptional level by both wt- and mutant p53 proteins. This leads to growth suppression or enhanced cell proliferation and chemo-resistance, respectively. In turn, the siRNA-mediated knock down of either mutant p53 or Plk2 proteins significantly curtails the growth properties of tumor cells and their chemo-resistance to anticancer treatments. Therefore, this paper identifies a novel tumor network including Plk2 and mutant p53 proteins whose triggering in response to DNA damage might disclose important implications for the treatment of human cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22134238     DOI: 10.4161/cc.10.24.18682

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  39 in total

Review 1.  Polo-like kinases: structural variations lead to multiple functions.

Authors:  Sihem Zitouni; Catarina Nabais; Swadhin Chandra Jana; Adán Guerrero; Mónica Bettencourt-Dias
Journal:  Nat Rev Mol Cell Biol       Date:  2014-07       Impact factor: 94.444

Review 2.  Mutant TP53 posttranslational modifications: challenges and opportunities.

Authors:  Thuy-Ai Nguyen; Daniel Menendez; Michael A Resnick; Carl W Anderson
Journal:  Hum Mutat       Date:  2014-02-11       Impact factor: 4.878

3.  YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins.

Authors:  Silvia Di Agostino; Giovanni Sorrentino; Eleonora Ingallina; Fabio Valenti; Maria Ferraiuolo; Silvio Bicciato; Silvano Piazza; Sabrina Strano; Giannino Del Sal; Giovanni Blandino
Journal:  EMBO Rep       Date:  2015-12-21       Impact factor: 8.807

Review 4.  Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.

Authors:  Xuetian Yue; Yuhan Zhao; Yang Xu; Min Zheng; Zhaohui Feng; Wenwei Hu
Journal:  J Mol Biol       Date:  2017-04-06       Impact factor: 5.469

5.  The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.

Authors:  Saisai Wei; Hongbo Wang; Chunwan Lu; Sarah Malmut; Jianqiao Zhang; Shumei Ren; Guohua Yu; Wei Wang; Dale D Tang; Chunhong Yan
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

Review 6.  p53 mutations in cancer.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Nat Cell Biol       Date:  2013-01       Impact factor: 28.824

7.  Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition.

Authors:  Marco Cordani; Elisa Oppici; Ilaria Dando; Elena Butturini; Elisa Dalla Pozza; Mercedes Nadal-Serrano; Jordi Oliver; Pilar Roca; Sofia Mariotto; Barbara Cellini; Giovanni Blandino; Marta Palmieri; Silvia Di Agostino; Massimo Donadelli
Journal:  Mol Oncol       Date:  2016-04-12       Impact factor: 6.603

8.  Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy?

Authors:  Sujata Choudhury; Vamsi K Kolukula; Anju Preet; Chris Albanese; Maria Laura Avantaggiati
Journal:  Cell Cycle       Date:  2013-03-06       Impact factor: 4.534

9.  Polo-like kinase 2 activates an antioxidant pathway to promote the survival of cells with mitochondrial dysfunction.

Authors:  Jie Li; Wenzhe Ma; Ping-yuan Wang; Paula J Hurley; Fred Bunz; Paul M Hwang
Journal:  Free Radic Biol Med       Date:  2014-06-02       Impact factor: 7.376

10.  DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53.

Authors:  S K Alam; V K Yadav; S Bajaj; A Datta; S K Dutta; M Bhattacharyya; S Bhattacharya; S Debnath; S Roy; L A Boardman; T C Smyrk; J R Molina; S Chakrabarti; S Chowdhury; D Mukhopadhyay; S Roychoudhury
Journal:  Cell Death Differ       Date:  2015-10-23       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.